胃肠道非处方药市场－全球产业规模、份额、趋势、机会及预测（按药物类别、适应症、最终用户、地区和竞争格局划分，2021-2031年）

全球消化器官系统胃肠道药物市场预计将从 2025 年的 415.1 亿美元成长到 2031 年的 608.8 亿美元，复合年增长率为 6.59%。

该市场主要由非处方笺药品组成，旨在无需医疗干预即可缓解便秘、腹泻和胃食道逆流等消化器官系统症状。推动这一市场成长的关键因素包括全球人口老化，导致慢性消化系统疾病需要持续管理，以及生活方式相关消化器官系统疾病的日益普遍。此外，世界各地的医疗保健系统都在推广自我管理策略，以降低营运成本并减轻基层医疗服务的压力。这一市场的需求规模庞大；根据欧洲自我护理产业委员会 (AESC) 的报告，到 2024 年，欧洲将售出 47 亿盒非处方药，用于治疗包括消化系统疾病在内的轻微健康问题。

儘管存在这些成长要素，但由于产品安全和标籤方面的严格法规结构，市场仍面临许多挑战。监管机构执行旨在保护消费者和防止不良反应的严格标准，这可能会延缓新配方的核准，并增加生产商的合规成本。这种严格的审查构成重大挑战，提高了市场准入门槛，并可能减缓全球非处方胃肠道药物行业的创新速度。

市场驱动因素

常见胃肠道疾病的日益普遍是全球消化器官系统成药市场的主要驱动因素。疫情后生活方式的改变加重了胃肠道疾病的负担，使得人们迫切需要便捷的治疗方法来缓解大肠激躁症（IBS）和消化不良等症状。这种日益增长的趋势促使消费者避免就医的繁琐，转而寻求处方笺以获得即时缓解。例如，2025年7月发表在《临床胃肠病学和肝病学》杂誌上的一项研究发现，成人功能性消化不良的盛行率从疫情前的8.3%上升到疫情后的11.9%，凸显了人们对有效消化器官系统治疗方法日益增长的需求。

市场扩张的进一步驱动力在于消费者对预防性医疗保健和自我治疗的日益重视。随着人们对自身健康采取更加积极主动的态度，非处方药在缓解轻微胃肠道症状方面的应用日益增多，这主要得益于值得信赖的品牌产品供应量的增加以及处方药重新归类为非处方药（OTC）。根据Haleon公司于2025年2月发布的2024年度报告，该公司消化健康及其他业务部门实现了5.5%的内部成长，营收达到20亿英镑，这主要得益于产品创新。这一趋势也与更广泛的健康行为相符。根据STADA于2025年6月发布的2025年健康报告，目前66%的欧洲人会定期进行大部分预防性体检，这意味着积极参与健康管理的人数增加了5个百分点，有利于自我护理领域的发展。

市场挑战

严格的产品标籤和安全法规结构对全球非处方胃肠成药市场的成长构成了重大障碍。虽然这些严格的标准对于保护消费者至关重要，但它们也给製造商带来了沉重的营运负担，因为新配方需要进行大量的临床试验和复杂的核准流程。高昂的成本和漫长的合规流程抑制了对新型胃肠道治疗药物的投资，有效地延缓了针对消化不良和胃灼热等症状的创新缓解措施的推出。因此，製造商被迫将资源从研发转移到合规，这提高了小型企业的进入门槛，并阻碍了市场动态。

监管产品的庞大数量凸显了营运挑战的规模。 2024年，欧洲自我护理产业协会报告称，该产业管理超过4,000种非处方药，这些药品由200多种活性药物成分製成。如此庞大的产品范围需要持续不断的监管回应，即使是标籤或安全评估的微小更新也会影响数千种产品线。这种监管密度直接阻碍了市场的灵活性，使企业难以快速回应胃肠道领域不断变化的消费者需求。

市场趋势

益生元和益生菌肠道健康补充剂的流行正在重塑市场格局，这主要归功于消费者日益关注优化肠道菌群以维持长期健康。这一趋势已超越了基础的消化缓解，发展到透过肠道生物调节来改善特定健康状况（例如免疫系统支持和功能性肠道疾病）的高级配方。製造商们积极回应，透过推出经临床检验、菌株特异性和高活性的产品，将这一品类提升到超越一般健康范畴的水平。这种转变也体现在专业公司的财务表现。根据BioGaia于2025年2月发布的“2024年1月至12月财务业绩报告”，该公司成人健康领域的年度净销售额预计将增长17%，这表明全球对靶向益生菌解决方案的需求强劲。

同时，消费者对「洁净标示」产品（而非合成药物）的偏好日益增长，推动了天然草本助消化剂的普及。消费者越来越倾向于选择薄荷、生姜和姜黄等植物成分，这些成分以其温和的功效和较少的副作用而闻名。这种需求促使非处方药生产商扩大其草本产品线，并改善现有产品线以吸引註重整体健康的消费者。 《全食杂誌》（WholeFoods Magazine）在其2025年2月刊中援引「CRN 2024消费者调查亮点」报道称，生姜作为助消化剂的使用率已上升至膳食补充剂使用者的13%，这印证了上述趋势。这表明，传统的植物疗法正逐渐融入现代人的日常自我护理习惯中。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球非处方胃肠道药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类别（泻药、胃肠道癌症治疗药物、胃酸分泌抑制剂、止泻药、质子帮浦阻断剂、H2受体拮抗剂、胃酸中和剂、肠道抗发炎药、止吐药）
  • 根据适应症（胃食道逆流或灼热、便秘、腹泻、晕动病、其他）
  • 依最终用户（医院药局、零售药局、网路药局、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美非处方胃肠道药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲非处方胃肠道药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区非处方胃肠道药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲胃肠道非处方药市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲非处方胃肠道药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球非处方胃肠道药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Viatris Inc.
• Sandoz Group AG
• Johnson & Johnson Services, Inc.
• Sun Pharmaceuticals Industries Limited
• Teva Pharmaceuticals Industries Ltd.
• Zydus Life science Ltd.
• Sanofi SA
• Bayer AG
• Pfizer Inc.
• GlaxoSmithKline Plc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Gastrointestinal OTC Drugs Market is projected to expand from USD 41.51 Billion in 2025 to USD 60.88 Billion by 2031, reflecting a CAGR of 6.59%. This market consists of non-prescription pharmaceutical formulations aimed at relieving digestive issues such as constipation, diarrhea, and gastroesophageal reflux disease without the need for a doctor's intervention. Key drivers of this growth include an aging global population requiring consistent management of chronic gastrointestinal conditions and the increasing prevalence of lifestyle-related digestive disorders. Additionally, healthcare systems around the world are promoting self-medication strategies to lower operational expenses and decrease the strain on primary care services. The magnitude of this demand is significant; the Association of the European Self-Care Industry reported that 4.7 billion packs of non-prescription medicines were sold in Europe in 2024 to address minor health concerns, including gastrointestinal ailments.

Despite these positive growth factors, the market encounters substantial obstacles due to strict regulatory frameworks concerning product safety and labeling. Regulatory authorities implement rigorous standards to ensure consumer protection and prevent adverse effects, a process that can prolong the approval of new formulations and escalate compliance costs for producers. This intense scrutiny serves as a major challenge, establishing high barriers to entry and potentially retarding the rate of innovation within the global gastrointestinal OTC industry.

Market Driver

The increasing prevalence of common gastrointestinal disorders acts as a major catalyst for the Global Gastrointestinal OTC Drugs Market. Lifestyle changes following the pandemic have intensified the burden of digestive ailments, creating a need for accessible treatments for conditions like irritable bowel syndrome (IBS) and indigestion. This rising incidence drives consumers to seek immediate relief through non-prescription avenues, avoiding the logistical challenges of clinical appointments. For example, a study published in Clinical Gastroenterology and Hepatology in July 2025 indicated that the prevalence of functional dyspepsia in adults rose from 8.3% before the pandemic to 11.9% afterward, highlighting the growing demand for effective digestive remedies.

Market expansion is further fueled by a growing consumer preference for preventive care and self-medication. As individuals take a more proactive approach to their health, the use of over-the-counter treatments for minor gastric issues has increased, supported by the greater availability of trusted brands and the reclassification of prescription drugs to OTC status. According to Haleon's 'Annual Report 2024', released in February 2025, the company's Digestive Health and Other segment achieved £2.0 billion in revenue with 5.5% organic growth, driven by product innovation. This trend is consistent with broader health behaviors; the 'STADA Health Report 2025', published in June 2025, noted that 66% of Europeans now attend most of their preventive checkups, reflecting a 5 percentage point rise in proactive health engagement that benefits the self-care sector.

Market Challenge

Rigorous regulatory frameworks regarding product labeling and safety present a significant barrier to the growth of the Global Gastrointestinal OTC Drugs Market. These strict standards, while necessary for consumer protection, place heavy operational demands on manufacturers by requiring extensive clinical testing and complex approval processes for new formulations. The substantial costs and lengthy timelines involved in meeting compliance requirements discourage investment in novel gastrointestinal therapies, effectively delaying the introduction of innovative relief options for conditions such as indigestion and heartburn. Consequently, manufacturers often must redirect resources from research and development to regulatory compliance, creating high entry barriers for smaller firms and stifling market dynamism.

The magnitude of this operational challenge is underscored by the vast volume of products subject to such oversight. In 2024, the Association of the European Self-Care Industry reported that the sector managed over 4,000 non-prescription medicines derived from more than 200 different active pharmaceutical ingredients. This extensive portfolio necessitates continuous regulatory maintenance, where even minor updates to labeling or safety evaluations can impact thousands of product lines. Such regulatory density directly hinders the market's agility, making it difficult for companies to respond quickly to evolving consumer needs within the gastrointestinal sector.

Market Trends

The market is being reshaped by the proliferation of prebiotic and probiotic gut health supplements, as consumers increasingly prioritize microbiome optimization for long-term wellness. This trend extends beyond basic digestive relief toward advanced formulations designed to address specific conditions, such as immune system support and functional bowel disorders, through gut modulation. Manufacturers are reacting by introducing strain-specific, high-potency products with clinical validation, thereby elevating the segment above general wellness. This shift is reflected in the financial results of specialized firms; according to BioGaia's 'Year-end report January - December 2024', published in February 2025, net sales in the company's Adult Health segment rose by 17% for the year, demonstrating strong global demand for targeted probiotic solutions.

Simultaneously, there is a rising consumer preference for natural and herbal digestive remedies, driven by a demand for "clean label" alternatives to synthetic drugs. Shoppers are actively seeking plant-based ingredients like peppermint, ginger, and turmeric, known for their minimal side effects and gentle efficacy. This demand is prompting OTC manufacturers to launch herbal adjacencies or reformulate existing lines to attract holistic-minded consumers. Validating this trend, WholeFoods Magazine reported in February 2025, citing 'Highlights from CRN's 2024 Consumer Survey', that usage of ginger as a digestive aid increased to 13% among supplement users, indicating the growing integration of traditional botanical solutions into modern self-care regimens.

Key Market Players

• Viatris Inc.
• Sandoz Group AG
• Johnson & Johnson Services, Inc.
• Sun Pharmaceuticals Industries Limited
• Teva Pharmaceuticals Industries Ltd.
• Zydus Life science Ltd.
• Sanofi SA
• Bayer AG
• Pfizer Inc.
• GlaxoSmithKline Plc.

Report Scope

In this report, the Global Gastrointestinal OTC Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastrointestinal OTC Drugs Market, By Drug Class

• Laxatives
• Gastrointestinal Cancer Treatments
• Gastric Acid Reducers
• Anti-Diarrheal
• Proton Pump Inhibitors
• H2 Inhibitors
• Gastric Acid Neutralizers
• Bowel Anti-Inflammatory
• Anti-Emetics

Gastrointestinal OTC Drugs Market, By Indication

• Gastroesophageal Reflux Disease or Heartburn
• Constipation
• Diarrhea
• Motion Sickness
• Others

Gastrointestinal OTC Drugs Market, By End User

• Hospitals Pharmacies
• Retail Pharmacies
• Online pharmacies
• Others

Gastrointestinal OTC Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal OTC Drugs Market.

Available Customizations:

Global Gastrointestinal OTC Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastrointestinal OTC Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics)
  • 5.2.2. By Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion Sickness, Others)
  • 5.2.3. By End User (Hospitals Pharmacies, Retail Pharmacies, Online pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Gastrointestinal OTC Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gastrointestinal OTC Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Gastrointestinal OTC Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Gastrointestinal OTC Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Gastrointestinal OTC Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gastrointestinal OTC Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. France Gastrointestinal OTC Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Gastrointestinal OTC Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Gastrointestinal OTC Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Gastrointestinal OTC Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia Pacific Gastrointestinal OTC Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gastrointestinal OTC Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Gastrointestinal OTC Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Gastrointestinal OTC Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Gastrointestinal OTC Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Gastrointestinal OTC Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. Middle East & Africa Gastrointestinal OTC Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gastrointestinal OTC Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Gastrointestinal OTC Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Gastrointestinal OTC Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. South America Gastrointestinal OTC Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gastrointestinal OTC Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Gastrointestinal OTC Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Gastrointestinal OTC Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gastrointestinal OTC Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Viatris Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sandoz Group AG
• 15.3. Johnson & Johnson Services, Inc.
• 15.4. Sun Pharmaceuticals Industries Limited
• 15.5. Teva Pharmaceuticals Industries Ltd.
• 15.6. Zydus Life science Ltd.
• 15.7. Sanofi SA
• 15.8. Bayer AG
• 15.9. Pfizer Inc.
• 15.10. GlaxoSmithKline Plc.

16. Strategic Recommendations

17. About Us & Disclaimer